The prognostic value of tumor-infiltrating lymphocytes in non-small cell lung cancer patients who received neoadjuvant chemotherapy followed by surgery

医学 危险系数 化疗 内科学 单变量分析 肿瘤科 肺癌 置信区间 肿瘤浸润淋巴细胞 多元分析 阶段(地层学) 病态的 新辅助治疗 放射治疗 癌症 免疫疗法 乳腺癌 古生物学 生物
作者
Zexin Hou,Lili Zhao,Lingjun Zou,benlan li
出处
期刊:Advances in Clinical and Experimental Medicine [Wroclaw Medical University]
卷期号:32 (8): 847-853 被引量:2
标识
DOI:10.17219/acem/159242
摘要

Background.The relationship between tumor-infiltrating lymphocyte (TIL) levels and the prognosis of patients with non-small cell lung cancer (NSCLC) who receive neoadjuvant chemotherapy followed by surgery is a problem that requires more research. Objectives.To evaluate the prognostic value of TIL levels in patients with NSCLC who received neoadjuvant chemotherapy followed by surgery. Materials and methods.Patients with NSCLC who received neoadjuvant chemotherapy followed by surgery in our hospital from December 2014 to December 2020 were selected for a retrospective analysis.Sections were stained with hematoxylin and eosin (H&E) to evaluate TIL levels in surgically-resected tumor tissues.Patients were divided into TIL-(low-level infiltration) and TIL+ (medium-to high-level infiltration) groups according to the recommended TIL evaluation criteria.Univariate (Kaplan-Meier) and multivariate (Cox) survival analyses were used to analyze the impact of clinicopathological features and TIL levels on prognosis.Results.The study involved 137 patients, including 45 who were TIL-and 92 who were TIL+.The median overall survival (OS) and disease-free survival (DFS) of the TIL+ group were higher than those of the TILgroup.The univariate analysis showed that smoking, clinical and pathological stages, and TIL levels, were the factors influencing OS and DFS.The multivariate analysis showed that smoking (OS, hazard ratio (HR): 1.881, 95% confidence interval (95% CI): 1.135-3.115,p = 0.014; DFS, HR: 1.820, 95% CI: 1.181-2.804,p = 0.007) and clinical stage III (DFS, HR: 2.316, 95% CI: 1.350-3.972,p = 0.002) were adverse factors affecting the prognosis of patients with NSCLC who received neoadjuvant chemotherapy followed by surgery.At the same time, TIL+ status was an independent factor for a good prognosis in OS (HR: 0.547, 95% CI: 0.335-0.894,p = 0.016) and DFS (HR: 0.445, 95% CI: 0.284-0.698,p = 0.001).Conclusions.Medium to high levels of TILs were associated with a good prognosis in NSCLC patients who received neoadjuvant chemotherapy followed by surgery.The levels of TILs are of prognostic value in this population of patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小二郎的应助被科研通管家采纳,获得10
刚刚
蜡笔小欣的应助被科研通管家采纳,获得10
1秒前
在水一方的应助被科研通管家采纳,获得10
1秒前
111发布了新的文献求助10
1秒前
1秒前
Rain发布了新的文献求助10
1秒前
DOC_XIONG的应助被科研通管家采纳,获得10
1秒前
秋风的应助被科研通管家采纳,获得10
1秒前
上官若男的应助被科研通管家采纳,获得10
1秒前
科目三的应助被科研通管家采纳,获得10
1秒前
田様的应助被科研通管家采纳,获得10
1秒前
2秒前
2秒前
7777777完成签到,获得积分10
2秒前
SciGPT的应助被科研通管家采纳,获得10
2秒前
wjy的应助被科研通管家采纳,获得10
2秒前
田様的应助被科研通管家采纳,获得10
2秒前
xx发布了新的文献求助10
2秒前
2秒前
2秒前
puritan发布了新的文献求助10
2秒前
酷波er的应助被科研通管家采纳,获得20
2秒前
所所的应助被科研通管家采纳,获得10
2秒前
Criminology34的应助被科研通管家采纳,获得10
3秒前
511发布了新的文献求助10
3秒前
情怀的应助被科研通管家采纳,获得10
3秒前
Criminology34的应助被科研通管家采纳,获得10
3秒前
3秒前
搜集达人的应助被科研通管家采纳,获得10
3秒前
Dritsw完成签到,获得积分10
4秒前
科研通AI2S的应助被lulu采纳,获得10
4秒前
5秒前
6秒前
研友_VZG7GZ的应助被tian-003采纳,获得30
7秒前
7秒前
Ascender发布了新的文献求助10
7秒前
xxxx_00发布了新的文献求助10
7秒前
pluto的应助被兴奋幻桃采纳,获得10
8秒前
xijvechi完成签到,获得积分10
8秒前
百川完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
CODESSA Version 2.13 for Windows 2000
Agricultural Ecology (Liao Yuncheng & Lin Wenxiong) 1000
Rosenblum, Global Change Biology 800
Berberine regulates the TLR4 signaling pathway to suppress hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells 520
Organizational Behavior 510
Derham on the Law of Set Off (德勒姆论抵消法/第五版) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 有机化学 化学工程 内科学 物理 生物化学 复合材料 催化作用 细胞生物学 人工智能 心理学 无机化学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 7846185
求助须知:如何正确求助?哪些是违规求助? 9366394
关于积分的说明 20650122
捐赠科研通 7442291
什么是DOI,文献DOI怎么找? 3341600
关于科研通互助平台的介绍 2485457
邀请新用户注册赠送积分活动 2364170